Definitive Healthcare Corp. (NASDAQ:DH) Receives $1.47 Average Target Price from Analysts

Definitive Healthcare Corp. (NASDAQ:DH) has been given a consensus recommendation of “Reduce” by the nine analysts that are covering the firm, Marketbeat Ratings reports. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and one has issued a strong buy rating on the company. The average 1 year target price among analysts that have covered the stock in the last year is $1.4714.

A number of analysts have commented on the stock. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Definitive Healthcare in a research report on Wednesday, June 3rd. Morgan Stanley lowered their price objective on Definitive Healthcare from $2.50 to $1.50 and set an “equal weight” rating for the company in a research report on Tuesday, August 11th. Robert W. Baird set a $1.10 price objective on Definitive Healthcare in a research note on Friday, May 8th. Bank of America restated an “underperform” rating and set a $0.70 target price on shares of Definitive Healthcare in a research report on Monday, June 29th. Finally, Wall Street Zen raised Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Sunday, July 26th.

Institutional Trading of Definitive Healthcare

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. increased its stake in shares of Definitive Healthcare by 564.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 8,716,725 shares of the company’s stock valued at $25,191,000 after acquiring an additional 7,404,363 shares in the last quarter. Arrowstreet Capital Limited Partnership bought a new position in Definitive Healthcare during the second quarter worth $4,247,000. Inspire Investing LLC boosted its stake in Definitive Healthcare by 505.7% during the fourth quarter. Inspire Investing LLC now owns 698,967 shares of the company’s stock worth $2,006,000 after acquiring an additional 583,562 shares in the last quarter. Millennium Management LLC grew its holdings in Definitive Healthcare by 230.9% in the fourth quarter. Millennium Management LLC now owns 332,087 shares of the company’s stock worth $953,000 after purchasing an additional 231,743 shares during the period. Finally, Jane Street Group LLC grew its holdings in Definitive Healthcare by 212.4% in the second quarter. Jane Street Group LLC now owns 328,410 shares of the company’s stock worth $1,281,000 after purchasing an additional 223,296 shares during the period. Institutional investors and hedge funds own 98.67% of the company’s stock.

Definitive Healthcare Stock Up 4.6%

Definitive Healthcare stock opened at $0.75 on Friday. The firm has a market cap of $80.51 million, a price-to-earnings ratio of -0.47, a PEG ratio of 8.90 and a beta of 1.35. Definitive Healthcare has a 52-week low of $0.61 and a 52-week high of $4.35. The company has a debt-to-equity ratio of 0.81, a quick ratio of 1.86 and a current ratio of 1.86. The firm has a 50 day moving average price of $0.73 and a two-hundred day moving average price of $0.98.

Definitive Healthcare (NASDAQ:DH) last posted its quarterly earnings data on Monday, August 10th. The company reported $0.05 EPS for the quarter, beating analysts’ consensus estimates of $0.04 by $0.01. Definitive Healthcare had a negative net margin of 72.28% and a positive return on equity of 3.55%. The company had revenue of $55.20 million for the quarter, compared to analyst estimates of $55.47 million. Definitive Healthcare has set its FY 2026 guidance at 0.180-0.200 EPS and its Q3 2026 guidance at 0.040-0.050 EPS. Equities analysts predict that Definitive Healthcare will post 0.06 EPS for the current year.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.